Novel and highly efficient transformation of carbon dioxide into 2-oxazolidinones over Al-MCM-41 mesoporous-supported ionic liquids

A type of Al-MCM-41 supported dual imidazolium ionic liquids were constructed and efficiently used as catalysts for the synthesis of 2-oxazolidinones from epoxides, amines, and CO2. The influence of the different catalysts and reaction parameters on the catalytic behaviours was investigated. Al-MCM-...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Environmental technology. - 1993. - 45(2024), 9 vom: 01. Apr., Seite 1855-1869
1. Verfasser: Hu, Yu Lin (VerfasserIn)
Weitere Verfasser: Liu, Xiao Bing, Yang, Li Li
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Environmental technology
Schlagworte:Journal Article 2-oxazolidinones Supported ionic liquid carbon dioxide cycloaddition mesoporous silica Carbon Dioxide 142M471B3J Ionic Liquids MCM-41 mehr... Oxazolidinones Amines Epoxy Compounds Silicon Dioxide 7631-86-9
Beschreibung
Zusammenfassung:A type of Al-MCM-41 supported dual imidazolium ionic liquids were constructed and efficiently used as catalysts for the synthesis of 2-oxazolidinones from epoxides, amines, and CO2. The influence of the different catalysts and reaction parameters on the catalytic behaviours was investigated. Al-MCM-41ILTiCl5 was identified as the most excellent catalyst because it could efficiently promote the three-component cycloaddition of CO2, epoxide, and amines to form the corresponding 2-oxazolidinones in high to excellent yields (84∼96%) with excellent selectivities (98∼99.7%). In addition, the recovery and reuse performances of Al-MCM-41@ILTiCl5 were examined. The catalyst could be recovered by simple filtration and reused six times without a change in the catalytic activity. Green reaction conditions, operational simplicity, feasibility, and sustainability of the functionalized catalyst are the main highlights of the present protocol
Beschreibung:Date Completed 12.03.2024
Date Revised 12.03.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1479-487X
DOI:10.1080/09593330.2022.2156816